Status:

RECRUITING

Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia

Lead Sponsor:

Thomas Benfield

Conditions:

Gram-negative Bacteremia

Urinary Tract Infection Bacterial

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

GNB5 is an investigator-initiated multicentre non-inferiority randomized controlled trial which aims to assess the efficacy and safety of shortened antibiotic for patients hospitalized with a Gram neg...

Detailed Description

Introduction: Prolonged use of antibiotics is closely related to antibiotic-associated infections, anti-microbial resistance and adverse drug events. The optimal duration of antibiotic treatment for G...

Eligibility Criteria

Inclusion

  • Age \>18 years
  • Blood culture positive for Gram-negative bacteria
  • Evidence of urinary tract source of infection (positive urine culture or at least one clinical symptom compatible with urinary tract infection)
  • Antibiotic treatment with antimicrobial activity to Gram-negative bacteria administrated within 12 hours of first blood culture
  • Temperature \<37.8°C at randomization
  • Clinically stabile at randomization (systolic blood pressure \> 90 mm Hg, heart rate \<100 beats/min., respiratory rate \<24/minute, peripheral oxygen saturation \> 90 %)
  • Oral and written informed consent

Exclusion

  • Antibiotic treatment (\>2 day) with antimicrobial activity to Gram-negative bacteria within 14 days of inclusion
  • Gram-negative bacteremia within 30 days of blood culture
  • Immunosuppression (Untreated HIV-infection, Neutropenia (absolute neutrophil count \< 1.0 x 109/l), Untreated terminal cancer, Receiving immunosuppressive agents (ATC-code L04A), Corticosteroid treatment (≥20 mg/day prednisone or the equivalent for \>14 days) within the last 30 days, Chemotherapy within the last 30 days, Immunosuppressed after solid organ transplantation, Asplenia)
  • Polymicrobial growth in blood culture
  • Bacteremia with non-fermenting Gram-negative bacteria (Acinetobacter spp, Burkholderia spp, Pseudomonas spp), Brucella spp, or Fusobacterium spp
  • Failure to remove source of infection within 72 hours of first blood culture (e.g. change of catheter á demeure)
  • Pregnancy or breastfeeding

Key Trial Info

Start Date :

March 11 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2026

Estimated Enrollment :

380 Patients enrolled

Trial Details

Trial ID

NCT04291768

Start Date

March 11 2020

End Date

October 1 2026

Last Update

February 8 2023

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

University Hospital of Aalborg

Aalborg, Denmark, 9000

2

University Hospital of Aarhus

Aarhus, Denmark, 8200

3

Rigshospitalet

Copenhagen, Denmark, 2100

4

Bispebjerg Hospital

Copenhagen, Denmark, 2400